Our Pipeline
The nervous system, which encompasses the brain, spinal cord, and peripheral nerves, is responsible for everything from movement and memory to emotion and survival. Developing therapies for neurological diseases is among the most complex and high-risk challenges in medicine, demanding not only scientific and clinical excellence but also bold thinking and unwavering commitment. At OnusBio, we are fearless innovators on a mission to transform the future of neurological care. Leveraging deep, hands-on experience across medicinal chemistry, clinical development, manufacturing, quality, regulatory, and supply chain, we combine cutting edge technology and advanced data analytics to overcome the complex challenges of treating nervous system disorders.
OnusBio currently has two active programs in discovery and preclinical stages of development, marching towards to the completion of IND-enabling studies within two years.
Neuropathy
We are developing a drug candidate that engages with specific targets that are scientifically proven.
Our lead compound has been rationally designed to achieve enhanced target selectivity, therapeutic efficacy, and an improved safety profile relative to current standard-of-care treatments. These attributes are driven by the innovative structural optimization of the molecule, which enables precise modulation of the intended biological pathway while minimizing off-target interactions. The compound’s unique chemical architecture reflects a structure-based drug design approach, informed by both mechanistic insight and advanced modeling techniques.
Traumatic Brain Injury
Our lead compound has demonstrated selective anti-inflammatory activity, which is critical therapeutic mechanism in the context of traumatic brain injuries. Ongoing studies are focused on validating target engagement through both in vitro and in vivo models to confirm the compound’s mechanism of action within the relevant neuroinflammatory pathways. In parallel, we are actively optimizing the compound’s manufacturability, including improvements in synthetic efficiency, scalability, and formulation, to ensure it meets the necessary standards for clinical development. These efforts are essential to enable the successful translation of scientific innovation into a viable therapeutic product with the potential to benefit patients suffering from neurological injury.
Join our community on social media and be the first to hear about new insights, events, and announcements